BACKGROUND Psoriasis of the intertriginous, anogenital, and facial regions remains a therapeutic challenge, with current algorithms lacking a topical agent that exhibits both high efficacy and minimal side effects. OBJECTIVE To assess the safety and efficacy of crisaborole 2% ointment-a nonsteroidal phosphodiesterase 4 inhibitor-in the treatment of intertriginous, anogenital, and facial psoriasis. METHODS A double-blind, randomized, vehicle-controlled trial was conducted in 21 participants. Participants were randomized 2:1 to receive 4 weeks of twice-daily treatment with either crisaborole 2% ointment (n = 14) or vehicle ointment (n = 7), followed by 4 weeks of open-label treatment with crisaborole 2% ointment. Disease severity was measured by using the Target Lesion Severity Scale (TLSS). RESULTS After 4 weeks, participants in the crisaborole group demonstrated 66% improvement compared with 9% in the vehicle group (P = .0011). Participants in the crisaborole group continued to experience improvement through the open-label phase, demonstrating 81% lesional improvement by week 8, with 71% of these participants achieving clinical clearance. There were no adverse events. LIMITATIONS The study was limited to a single tertiary care center and small sample size. CONCLUSION Treatment with crisaborole 2% ointment was well-tolerated and led to clinical improvement in participants with intertriginous, anogenital, or facial psoriasis.

中文翻译：

---

2％的Crisaborole软膏用于治疗三尖瓣，肛门生殖器和面部牛皮癣：一项双盲，随机，赋形剂对照试验。

背景技术牛皮癣的三头肌，肛门生殖器和面部区域仍然是一种治疗挑战，目前的算法缺乏表现出高功效和最小副作用的局部用药。目的评估2％克雷伯伯丁软膏（一种非甾体磷酸二酯酶4抑制剂）在三尖瓣，肛门生殖器和面部牛皮癣治疗中的安全性和有效性。方法在21名参与者中进行了一项双盲，随机，车辆对照试验。参与者被随机以2：1的比例接受2周每天两次的瑞卡波罗2％软膏（n = 14）或赋形剂软膏（n = 7）的治疗，为期4周，然后接受4周瑞卡波罗2％软膏的开放标签治疗。疾病严重程度通过使用目标病变严重程度量表（TLSS）进行测量。结果4周后，沙丁胺醇组的参与者表现出66％的改善，而赋形剂组则为9％（P = .0011）。crisaborole组的参与者在开放标签阶段持续改善，表明到第8周时病灶改善了81％，其中71％的参与者达到了临床清除率。没有不良事件。局限性该研究仅限于单个三级护理中心且样本量较小。结论2％的克雷莎伯乐软膏治疗耐受性良好，并导致三叉性，肛门生殖器或面部牛皮癣患者的临床改善。在第8周时，病灶改善了81％，其中71％的受试者达到了临床清除率。没有不良事件。局限性该研究仅限于单个三级护理中心且样本量较小。结论2％的克雷莎伯乐软膏治疗耐受性良好，并导致三尖瓣，肛门生殖器或面部牛皮癣患者的临床改善。在第8周时，病灶改善了81％，其中71％的受试者达到了临床清除率。没有不良事件。局限性该研究仅限于单个三级护理中心且样本量较小。结论2％的克雷莎伯乐软膏治疗耐受性良好，并导致三尖瓣，肛门生殖器或面部牛皮癣患者的临床改善。